CTI BioPharma (FRA:CEPS) Stock Based Compensation : €10.41 Mil (TTM As of Mar. 2023)

View and export this data going back to 2007. Start your Free Trial

What is CTI BioPharma Stock Based Compensation?

CTI BioPharma's Stock Based Compensation for the three months ended in Mar. 2023 was €2.34 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2023 was €10.41 Mil.

CTI BioPharma Stock Based Compensation Historical Data

The historical data trend for CTI BioPharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Stock Based Compensation Chart

CTI BioPharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Stock Based Compensation

Get a 7-Day Free Trial

5.60

4.65

3.55

4.20

9.47

CTI BioPharma Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Stock Based Compensation	Get a 7-Day Free Trial															1.53	2.40	2.85	2.82	2.34

CTI BioPharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €10.41 Mil.

CTI BioPharma Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

CTI BioPharma (FRA:CEPS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (FRA:CEPS) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121

Website

https://www.ctibiopharma.com

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (FRA:CEPS) Headlines

No Headlines